SCHEMBL27091452

SCHEMBL27091452

CCc1cc(Nc2ncnc(Nc3ccc4ccccc4c3NS(C)(=O)=O)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 18/20 0.59
▸ FGFR1 P11362 1/20 0.56
▸ FGFR2 P21802 1/20 0.56
▸ FGFR4 P22455 1/20 0.56
▸ FGFR3 P22607 1/20 0.56
▸ KDR P35968 1/20 0.56
▸ INSR P06213 2/20 0.54
▸ IGF1R P08069 2/20 0.54
▸ ALK Q9UM73 2/20 0.54
▸ BMPR1B O00238 1/20 0.54
▸ PLK4 O00444 1/20 0.54
▸ GAK O14976 1/20 0.54
▸ ERN1 O75460 1/20 0.54
▸ STK10 O94804 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ FYN P06241 1/20 0.54
▸ NPM1 P06748 1/20 0.54
▸ FES P07332 1/20 0.54
▸ YES1 P07947 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30741326 1.00 EGFR (0.59) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL30741318 0.90 EGFR (0.59) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL27091419 0.90 EGFR (0.59) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL30741323 0.90 FGFR3 (0.62) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL27091505 0.90 FGFR3 (0.62) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL30741328 0.87 EGFR (0.63) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL27091332 0.87 EGFR (0.63) EGFRFGFR1FGFR2FGFR4FGFR3
SCHEMBL29785260 0.82 EGFR (0.71) EGFR
SCHEMBL27091483 0.82 EGFR (0.71) EGFR
SCHEMBL29785315 0.82 EGFR (0.64) EGFRINSRIGF1RALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051940-A1 SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2024-02-15 — — US claimed
US-20240051940-A1 SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2024-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051940-A1 SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF EGFR, ERBB2, ERBB4 EGFR 1/4885FGFR1 125/4885FGFR2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback